Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 450, 1157-1159 (20 December 2007) | doi:10.1038/4501157a; Published online 19 December 2007
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellows
- The Mathematical Biosciences Institute
- Ohio, USA
Associate Scientific Manager / Scientific Manager-Organic / Medicinal Chemistry
- Syngene International
- Bangalore, Karnataka 560099 India
Professor's little helper
Barbara Sahakian1 & Sharon Morein-Zamir1
- Barbara Sahakian and Sharon Morein-Zamir are at the University of Cambridge, Department of Psychiatry and the MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute, Cambridge CB2 2QQ, UK.
Abstract
The use of cognitive-enhancing drugs by both ill and healthy individuals raises ethical questions that should not be ignored, argue Barbara Sahakian and Sharon Morein-Zamir.
Today there are several drugs on the market that improve memory, concentration, planning and reduce impulsive behaviour and risky decision-making, and many more are being developed. Doctors already prescribe these drugs to treat cognitive disabilities and improve quality of life for patients with neuropsychiatric disorders and brain injury.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
